

Cadila Healthcare announces settlement with Depomed

16 April 2014 | News | By BioSpectrum Bureau

Cadila Healthcare announces settlement with Depomed



Cadila Healthcare Limited, a global pharmaceuticals company, and Zydus Pharmaceuticals (USA), Inc., a leading generic pharmaceutical company in the United States, today announced that they have entered into a settlement agreement with Depomed, Inc. to settle their ongoing patent infringement litigation related to Gralise(gabapentin)300 mg and 600 mg tablets.

The settlement permits Cadila and Zydus to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances. Other terms of the settlement were not disclosed.

The agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey.